Download presentation
Presentation is loading. Please wait.
Published byAlbert Bosman Modified over 6 years ago
1
Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: An open-label, blinded end point, randomized prospective trial (VitD-CHF trial) Nicolas F. Schroten, MD, Willem P.T. Ruifrok, MD, PhD, Lennaert Kleijn, MD, Martin M. Dokter, BASc, Herman H. Silljé, PhD, Hiddo J. Lambers Heerspink, PhD, Stephan J.L. Bakker, MD, PhD, Ido P. Kema, PhD, Wiek H. van Gilst, PhD, Dirk J. van Veldhuisen, MD, PhD, Hans L. Hillege, MD, PhD, Rudolf A. de Boer, MD, PhD American Heart Journal Volume 166, Issue 2, Pages e2 (August 2013) DOI: /j.ahj Copyright © 2013 Mosby, Inc. Terms and Conditions
2
Figure 1 Patient enrollment.
American Heart Journal , e2DOI: ( /j.ahj ) Copyright © 2013 Mosby, Inc. Terms and Conditions
3
Figure 2 Mean (SE) change in 25(OH)D from baseline. Data are log2 transformed; therefore, an increase of one is equal to a doubling of the value from baseline. American Heart Journal , e2DOI: ( /j.ahj ) Copyright © 2013 Mosby, Inc. Terms and Conditions
4
Figure 3 Correlation of absolute change in 25(OH)D between baseline and end of study with baseline 25(OH)D. The difference in slope of the regression lines depicts the interaction between baseline 25(OH)D and change in 25(OH)D between the treatment groups. American Heart Journal , e2DOI: ( /j.ahj ) Copyright © 2013 Mosby, Inc. Terms and Conditions
5
Figure 4 Mean (SE) treatment effect of VitD3 compared with control after 3 and 6 weeks of treatment on PRA and PRC, expressed as percent change from baseline. American Heart Journal , e2DOI: ( /j.ahj ) Copyright © 2013 Mosby, Inc. Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.